NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: james who wrote (258)	1/17/1998 9:19:00 PM
From: Arthur Radley	Read Replies (2) of 328

James, The word/rumor is that Nexstar is having problems selling their Ambisone drug due to the high cost. It appears that they are trying to sell it for about $900 for a treatment when two other companies have competing drugs that sell for about $240 and $400 each. Supposedly, the University of Wisconsin Hospital and maybe others have stop using the drug because of this issue. I agree that NXTR could be a short squeeze candidate but it would take some excellent news to do so.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next